Monteverde & Associates PC, a New York-based class action securities firm, has announced investigations into four separate merger transactions involving Arcosa, Inc., Crinetics Pharmaceuticals, Inc., Leggett & Platt, Incorporated, and LivePerson, Inc. The firm, led by Juan Monteverde, states it is reviewing these deals to determine if shareholder interests were adequately protected during the negotiation processes. With shareholder votes scheduled between August 20 and September 4, 2026, investors in these companies face imminent decisions on whether to approve the proposed sales.

The investigation covers a diverse set of industries, including industrial products, pharmaceuticals, furniture components, and artificial intelligence software. Monteverde & Associates PC highlights its recognition as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report to underscore its capacity to litigate complex securities matters. The firm emphasizes that shareholders should consult legal counsel before voting, noting that prior results do not guarantee future outcomes in litigation.

Transaction Details

The firm provided specific details regarding the consideration offered to shareholders in each proposed transaction. These figures represent the core economic terms that shareholders will vote on in the coming weeks.

Shareholder Actions Required

Shareholders of the four companies are urged to act before their respective deadlines. For Arcosa, the vote is scheduled for September 4, 2026. Crinetics Pharmaceuticals shareholders must vote by August 28, 2026. Both Leggett & Platt and LivePerson have shareholder votes scheduled for August 20, 2026.

Monteverde & Associates PC advises investors to ask potential legal representatives specific questions regarding their litigation history, including whether they file class actions, go to court, and have recovered money for shareholders recently. The firm offers its services free of charge, stating there is no cost or obligation for shareholders to seek information or representation.

About the Firm

Monteverde & Associates PC operates from the Empire State Building in New York City. The firm describes itself as a national class action securities practice with experience in trial and appellate courts, including the U.S. Supreme Court. Juan Monteverde serves as the lead attorney for these investigations. The firm maintains that no company, director, or officer is above the law and encourages shareholders with concerns to contact them directly via email or telephone.

MarketsandMarkets has released a new report projecting the global dermatology devices market to reach USD 17.73 billion by 2031, growing from USD 9.32 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. This significant expansion reflects accelerating adoption of advanced diagnostic and therapeutic technologies across medical and aesthetic sectors worldwide. The forecast period covers 2026 to 2031, with North America identified as the leading regional market in 2025.

The market’s growth trajectory is underpinned by several key drivers, including the rising prevalence of skin disorders such as acne, psoriasis, eczema, skin cancer, and pigmentation issues. Simultaneously, there is surging global demand for aesthetic procedures, supported by growing awareness of skin health, rising disposable incomes, and an aging population seeking anti-aging and rejuvenation treatments. Patients are increasingly preferring minimally invasive and non-invasive procedures, which has boosted demand for advanced treatment technologies in hospitals, dermatology clinics, and aesthetic centers.

Market Segmentation and Technology Trends

The dermatology devices market is segmented by technology, type, application, end user, and region. In 2025, the laser-based segment held the largest market share at 37.4%, driven by its widespread use in hair removal, skin rejuvenation, scar revision, tattoo removal, and vascular lesion treatment. Treatment devices accounted for the largest share by type, holding 61.0% of the market in 2025. Aesthetic therapeutic applications are expected to grow at the highest CAGR during the forecast period.

Technological innovations are enhancing precision and safety. Advances in laser systems, radiofrequency (RF), high-intensity focused ultrasound (HIFU), light-based therapies, and cryotherapy are improving clinical outcomes. The integration of high-resolution imaging modalities, such as optical coherence tomography (OCT) and high-frequency ultrasound (HFUS), enables earlier detection of skin disorders, reducing the need for invasive diagnostics.

Competitive Landscape and Regional Insights

North America dominated the market in 2025, benefiting from well-established healthcare infrastructure, high disposable incomes, favorable reimbursement policies, and strong patient awareness. The region also sees frequent product launches and regulatory approvals. Beauty centers are expected to be the fastest-growing end-user segment, reflecting the shift toward cosmetic dermatology.

Key players identified as star players due to their strong market presence include Bausch Health Companies Inc., Sisram Medical Ltd., AbbVie Inc., InMode Ltd., and BTL Group of Companies. Startups and SMEs such as Dimed Laser, Sciton, Fotona, Lynton Lasers Ltd., Astanza Laser, and Courage+Khazaka Electronic GmbH have secured strong footholds in specialized niche areas. Other notable companies include Alma Lasers, Cutera, Cynosure, Lumenis, Solta Medical, Bruker Corporation, Carl Zeiss, Candela Corporation, Genesis Biosystems, HEINE Optotechnik, Michelson Diagnostics, PhotoMedex, Leica Microsystems, Olympus Corporation, FotoFinder Systems, Canfield Scientific, Beijing Toplaser Technology, DermLite, Syneron Medical, Aerolase, and Bovie.

What the Numbers Show

The data indicates a structural shift toward aesthetic applications, with this segment projected to record the highest growth rate. While hospitals and clinics currently hold the largest share due to complex medical treatments, the rapid expansion of beauty centers suggests that consumer-driven cosmetic procedures are becoming a primary growth engine. The dominance of laser technology (37.4%) underscores its versatility in both medical and aesthetic contexts, positioning it as the core driver of near-term revenue expansion.